Hanover - Delayed Quote EUR

argenx SE (1AEA.HA)

Compare
585.00
-10.00
(-1.68%)
As of 8:01:15 AM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,858,657
1,226,316
410,747
497,277
41,243
Cost of Revenue
194,110
117,835
29,431
--
--
Gross Profit
1,664,547
1,108,481
381,316
497,277
41,243
Operating Expense
1,920,784
1,529,119
1,105,234
857,176
521,811
Operating Income
-256,237
-420,638
-723,918
-359,899
-480,568
Net Non Operating Interest Income Expense
142,260
92,058
22,548
2,393
4,718
Other Income Expense
51,470
24,084
-27,942
-42,239
-129,502
Pretax Income
-62,507
-304,496
-729,314
-399,743
-605,352
Tax Provision
-22,214
-9,443
-19,720
8,522
3,103
Net Income Common Stockholders
-40,293
-295,053
-709,594
-408,265
-608,455
Diluted NI Available to Com Stockholders
-40,293
-295,053
-709,594
-408,265
-608,455
Basic EPS
-0.70
-5.16
-13.05
-7.99
-13.40
Diluted EPS
-0.78
-5.16
-13.05
-7.99
-13.40
Basic Average Shares
59,509.95
57,169.25
54,381.37
51,075.83
45,410.44
Diluted Average Shares
63,311.71
57,169.25
54,381.37
51,075.83
45,410.44
Total Operating Income as Reported
-263,319
-425,049
-720,341
-348,746
-477,617
Total Expenses
2,114,894
1,646,954
1,134,665
857,176
521,811
Net Income from Continuing & Discontinued Operation
-40,293
-295,053
-709,594
-408,265
-608,455
Normalized Income
-78,036.54
-322,664.32
-683,066.22
-377,430.53
-513,918.54
Interest Income
144,298
92,962
24,741
3,489
5,119
Interest Expense
2,038
904
2,193
1,096
401
Net Interest Income
142,260
92,058
22,548
2,393
4,718
EBIT
-60,469
-303,592
-727,121
-398,647
-604,951
EBITDA
-60,469
-192,285
-622,779
-392,780
-601,034
Reconciled Cost of Revenue
194,110
8,894
29,431
--
--
Reconciled Depreciation
--
111,307
104,342
5,867
3,917
Net Income from Continuing Operation Net Minority Interest
-40,293
-295,053
-709,594
-408,265
-608,455
Total Unusual Items Excluding Goodwill
58,552
28,495
-27,265
-42,239
-129,502
Total Unusual Items
58,552
28,495
-27,265
-42,239
-129,502
Normalized EBITDA
-119,021
-220,780
-595,514
-350,541
-471,532
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
20,808.46
883.68
-737.22
-11,404.53
-34,965.54
12/31/2020 - 9/24/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2QK.F Scholar Rock Holding Corporation
34.20
-0.58%
 
8AP.SG Agios Pharmaceuticals Inc
31.40
0.00%
 
ISI.F Ionis Pharmaceuticals, Inc.
31.02
-2.45%
 
ISI.MU Ionis Pharmaceuticals Inc
31.47
-1.13%
 
VX1.F Vertex Pharmaceuticals Incorporated
459.45
-1.42%
 
BHVN Biohaven Ltd.
32.06
-13.77%
 
RVMD Revolution Medicines, Inc.
38.34
-5.89%
 
INCY Incyte Corporation
70.26
-4.41%
 
ALNY Alnylam Pharmaceuticals, Inc.
243.53
-1.30%